NSE: IPCALAB | BSE: 524494

Falling Comet

Download real time

1361.80 2.70 (0.20%)

29.45% Gain from 52W Low

254.9K NSE+BSE Volume

NSE 18 Jun, 2025 3:31 PM (IST)

34,549.4

Market Cap

High in industry

0.8

Beta 1Year

Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Search Inside the pdf :

Ipca Laboratories Ltd.

31 May 2025

1361.80

0.20%

Ipca Laboratories (IPCA IN) Q4FY25 Result Update Muted...

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

Ipca Labs (IPCA) reported EBITDA of Rs4.1bn (up 35% YoY), was in line with our estimates. However, mgmt. FY26 guidance of 8-10% revenue growth was below our expectations (12-13%). Resultant, our FY26E and FY27E EPS stands reduced by 4-8%. API and generic business growth were muted in FY25; recovery will be gradual. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. Turnaround in Unichem remains on track with...

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

14 Feb 2025

1361.80

0.20%

IPCA LABORATORIES

Accumulate: Ipca Laboratories Ltd.

Prabhudas Lilladhar

Prabhudas Lilladhar decreased Accumulate price target of Ipca Laboratories Ltd. to 1525.0 on 31 May, 2025.

Ipca Laboratories Ltd.

14 Feb 2025

1361.80

0.20%

Ipca Laboratories (IPCA IN) Q3FY25 Result Update EBITDA...

Accumulate: Ipca Laboratories Ltd.

Prabhudas Lilladhar

Domestic formulation growth was aided by 5-6% each price and volume. Ipca Labs (IPCA) reported EBITDA of Rs4.6bn (up 35% YoY), 7% beat to our estimates. Our FY26E and FY27E EPS broadly remains unchanged. The broadbased revenue growth in 9M provides comfort while export API and generic should recover in coming quarters. Domestic formulation business, which now contributes 40% of revenues and ~60% of EBITDA, continued to outperform and grow at healthy levels. Turnaround in Unichem remains on track with...

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.

Ipca Laboratories Ltd.

27 Dec 2024

1361.80

0.20%

Scaling US operations/outpacing IPM to aid robust earnings growth

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Following a muted performance in the US over the past eight years due to compliance issues, IPCA is well-poised to revive its US business through new product launches, relaunches, stable pricing in its base business, and the integration of the Unichem business over the next 12-24M.

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

18 Nov 2024, 12:00AM

1361.80

0.20%

IPCA LABORATORIES

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

Ipca Laboratories Ltd. is trading below all available SMAs

Ipca Laboratories Ltd.

14 Nov 2024

1361.80

0.20%

US recovery, Unichem acquisition set to drive growth

Buy: Ipca Laboratories Ltd.

Target

Sharekhan

Quarterly revenues reached Rs. 2,355 crore, marking a 16% y-o-y increase and a 13% rise from the
previous quarter. Profit after tax (PAT) came in strong at Rs. 245 crore, up 39% as compared to last year and 23%, sequentially.

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.

Ipca Laboratories Ltd.

14 Oct 2024

1361.80

0.20%

At an inflexion point

Buy: Ipca Laboratories Ltd.

Recommendation Target

Motilal Oswal

After three years of earnings deterioration, IPCA is well-poised to deliver strong earnings growth over FY24-27.

Number of FII/FPI investors increased from 282 to 294 in Mar 2025 qtr.

Ipca Laboratories Ltd.

30 Sep 2024

1361.80

0.20%

Bayshore integration to unlock growth

Buy: Ipca Laboratories Ltd.

Target

Sharekhan

Ipca’s board would discuss the strategic integration of Bayshore Pharmaceuticals’ generics business into Unichem Pharma (USA) Inc on September 30, 2024.

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

14 Aug 2024

1361.80

0.20%

Strong Q1; UniChem’s turnaround sustainable

Buy: Ipca Laboratories Ltd.

Recommendation Target

Sharekhan

Ipca Laboratories Limited’s (Ipca) earnings came above our estimates, as sales grew 32.9% y-o-y to Rs. 2,092 crore. Sales growth was led by 11.6% y-o-y growth in domestic branded formulations.

Ipca Laboratories Ltd. has an average target of 1756.67 from 3 brokers.

Ipca Laboratories Ltd.

14 Aug 2024

1361.80

0.20%

Domestic formulation drives earnings

Neutral: Ipca Laboratories Ltd.

Target

Motilal Oswal

IPCA delivered better-than-expected 1QFY25 earnings. The improved performance in the domestic formulation (DF) segment was offset to some extent by a subdued show in exports and API segment.

Prabhudas Lilladhar decreased Accumulate price target of Ipca Laboratories Ltd. to 1525.0 on 31 May, 2025.

Is Ipca Laboratories Ltd. worth buying?

365 Votes:

Buy 80.27%

Sell 9.86%

Hold 9.86%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf